Kane Biotech (KNBIF) 0.0230 $KNBIF
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Jun 25, 10:49AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
announced that on June 23, 2015, it issued 254,178 common shares of the Corporation ("Common Shares" in payment of $12,708.91 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at June 18, 2015. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on June 23, 2015. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Board Members
Marketwired - Thu Jun 25, 10:42AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 22, 2015 (the "Meeting", the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard and Mark Ahrens-Townsend. Each Director is to serve for a term of one year or until their successors are elected or appointed.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Joint Development Agreement and Channel Expansion
Marketwired - Wed May 13, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's current focus is on the animal oral care market.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Change in Executive Leadership
Marketwired - Mon May 11, 6:31AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.
KNE.VN: 0.035 (unch)
Kane Biotech Summarizes Compelling Oral Care Study Results
Marketwired - Thu Mar 26, 7:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.
KNE.VN: 0.035 (unch)
Kane Biotech Introduces bluestem(TM)
Marketwired - Thu Feb 12, 8:26AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms announces that it will be introducing the company's bluestem pet oral care brand in the over the counter (OTC) retail market.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Grant of Options
Marketwire Canada - Mon Jan 12, 9:01AM CST
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, announces that the Company has granted an aggregate of 3,865,000 stock options at an exercise price of $.07 per common share to directors, management, employees and consultants of the Company. The options pursuant to the Corporation's stock option plan and are subject to TSX Venture Exchange acceptance. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to resale restriction for a period of four months from the date of the grant.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Second Closing of Private Placement Offering
Marketwired - Wed Dec 17, 10:28AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech", a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, has completed the second closing of its current private placement offering (the "Offering" with additional aggregate gross proceeds to the Company of $50,000 from the sale of 1,000,000 units ("Units" at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one Share purchase warrant (a "Warrant". Each Warrant will expire 18 months from the date the Warrant is issued (the "Expiry Date" and will entitle the holder to purchase one Share at a price of $0.06 up to the Expiry Date. The total amount raised by Kane at the first and second closings of the Offering is $1,225,000 from the sale of 24,500,000 Units.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest
Marketwired - Thu Jun 25, 10:49AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Corporation"
announced that on June 23, 2015, it issued 254,178 common shares of the Corporation ("Common Shares" in payment of $12,708.91 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note" as at June 18, 2015. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange". The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on June 23, 2015. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies. KNE.VN: 0.035 (unch)
Kane Biotech Announces Board Members
Marketwired - Thu Jun 25, 10:42AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company's Annual and Special Meeting of shareholders held on June 22, 2015 (the "Meeting"
, the following individuals have been elected to the board of directors; Philip Renaud (Chairman), Dr. Arvind Joshi, Mark Nawacki, Dr. Sarah Prichard and Mark Ahrens-Townsend. Each Director is to serve for a term of one year or until their successors are elected or appointed. KNE.VN: 0.035 (unch)
Kane Biotech Announces Joint Development Agreement and Channel Expansion
Marketwired - Wed May 13, 7:02AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), is a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's current focus is on the animal oral care market.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Change in Executive Leadership
Marketwired - Mon May 11, 6:31AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms today announced Gord Froehlich will retire as Chief Executive Officer. The Board has appointed Mark Ahrens-Townsend as President and CEO to replace Froehlich, effective May 11, 2015.
KNE.VN: 0.035 (unch)
Kane Biotech Summarizes Compelling Oral Care Study Results
Marketwired - Thu Mar 26, 7:01AM CDT
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.
KNE.VN: 0.035 (unch)
Kane Biotech Introduces bluestem(TM)
Marketwired - Thu Feb 12, 8:26AM CST
Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms announces that it will be introducing the company's bluestem pet oral care brand in the over the counter (OTC) retail market.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Grant of Options
Marketwire Canada - Mon Jan 12, 9:01AM CST
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, announces that the Company has granted an aggregate of 3,865,000 stock options at an exercise price of $.07 per common share to directors, management, employees and consultants of the Company. The options pursuant to the Corporation's stock option plan and are subject to TSX Venture Exchange acceptance. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to resale restriction for a period of four months from the date of the grant.
KNE.VN: 0.035 (unch)
Kane Biotech Announces Second Closing of Private Placement Offering
Marketwired - Wed Dec 17, 10:28AM CST
Kane Biotech Inc. (TSX VENTURE: KNE) (the "Company" or "Kane Biotech"
, a biotechnology company engaged in the development of products that prevent and remove microbial biofilms, has completed the second closing of its current private placement offering (the "Offering" with additional aggregate gross proceeds to the Company of $50,000 from the sale of 1,000,000 units ("Units" at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Company (a "Share" and one Share purchase warrant (a "Warrant". Each Warrant will expire 18 months from the date the Warrant is issued (the "Expiry Date" and will entitle the holder to purchase one Share at a price of $0.06 up to the Expiry Date. The total amount raised by Kane at the first and second closings of the Offering is $1,225,000 from the sale of 24,500,000 Units. KNE.VN: 0.035 (unch)
